新股評級 | 瑞科生物-B：衝擊 “港股 HPV 疫苗第一股”

格隆匯
2022.03.21 00:59

引入 3 名基石投資者

今天為大家帶來【瑞科生物-B】的新股評級。本評級主要圍繞基本盤、實操盤兩大維度，針對目標公司各項核心指標進行打分評級，滿分為 10 分，各指標單獨評分，按 “(權重佔比 * 分數) 之和” 計算，最終結果按照四捨五入得到。格隆匯新股研究根據已公開數據及獨家的內部評級體系，給予【瑞科生物-B】的新股綜合評估分數為【8.2】(滿分為 10 分），如下圖：

Source: 格隆匯 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.